Total medical devices industry venture financing deals in Q3 2020 worth $4.48bn were announced globally, according to GlobalData’s deals database.
Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
The value marked a decrease of 3.6% over the previous quarter and a rise of 32.8% when compared with the last four-quarter average, which stood at $3.37bn.
Comparing deals value in different regions of the globe, North America held the top position, with total announced deals in the period worth $2.63bn. At the country level, the US topped the list in terms of deal value at $2.62bn.
In terms of volumes, North America emerged as the top region for medical devices industry venture financing deals globally, followed by Asia-Pacific and then Europe.
The top country in terms of venture financing deals activity in Q3 2020 was the US with 155 deals, followed by China with 64 and Australia with 21.
In 2020, as of the end of Q3 2020, medical devices venture financing deals worth $12.37bn were announced globally, marking an increase of 60.4% year on year.
Medical devices industry venture financing deals in Q3 2020: Top deals
The top five medical devices industry venture financing deals accounted for 19.7% of the overall value during Q3 2020.
The combined value of the top five medical devices venture financing deals stood at $881.86m, against the overall value of $4.48bn recorded for the month.
The top five medical devices industry deals of Q3 2020 tracked by GlobalData were:
1) Andreessen Horowitz, Bain Capital Life Sciences, BrightEdge Fund, Catalio Capital Management, Colorectal Cancer Alliance, Cormorant Asset Management, Data Collective Venture Capital, EcoR1 Capital, Farallon Capital Management, Fidelity Management & Research, GV Management Co, Janus Henderson Investors, Kaiser Permanente Ventures, Novartis Venture Fund, Perceptive Advisors, Polaris Partners, RA Capital Management, Roche Venture Fund, Rock Springs Capital Management, Sands Capital Management, Section 32, Soleus Capital Management and T Rowe Price Associates’ $270m venture financing of Freenome
2) The $257m venture financing of Thrive Earlier Detection by Bain Capital Life Sciences, Brown Advisory, Casdin Capital, Driehaus Capital Management, Intermountain Ventures, Janus Henderson Investors, Lux Capital, Moore Strategic Ventures, Perceptive Advisors, Rock Springs Capital Management, Sands Capital Management, Section 32 and T Rowe Price Associates
3) Boston Scientific, Merck Global Health Innovation Fund, Novo Holdings, Samsung Catalyst Fund and Vivo Capital’s $137m venture financing of Preventice
4) The $121m venture financing of Mount Sinai Genomics by BlackRock, Connecticut Innovations, Decheng Capital, Deerfield ManagementLP, Moore Strategic Ventures, Oak HC/FT Partners, Section 32 and The Blackstone Group
5) Yestar Healthcare HoldingsLtd’s venture financing of Shanghai Anbaida Investment Management Consulting(Emphasis) for $96.86m.
Verdict deals analysis methodology
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.